MCM
SVA

MAI Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

MAI Capital Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
3
– – ﹤0.01% 5158
2025
Q4 		$0 Hold
3
– – ﹤0.01% 4511
2025
Q3 		$0 Hold
3
– – ﹤0.01% 4174
2025
Q2 		$0 Buy
+3
New – ﹤0.01% 4062

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

MAI Capital Management's SVA Position: Q1 2026 in Review

MAI Capital Management held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 3 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5158.

MAI Capital Management first reported a position in SVA in Q2 2025 and has held it in 4 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • MAI Capital Management held 3 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
  • MAI Capital Management left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #5158 holding.
  • MAI Capital Management first reported a position in Sinovac Biotech, Ltd in Q2 2025 and has held it in 4 quarters since.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.